M. Alexander Otto, PA, MMS January 18, 2023 A randomized clinical trial from India raises the possibility of huge cost savings by using much lower doses of immunotherapy. The researchers used just 6% of the recommended dose of nivolumab instead of the full dose in their treatment of patients with advanced head and neck cancer, and the addition of...
Tag: <span>Nivolumab</span>
Post
Relatlimab Plus Nivolumab a ‘Game Changer’ in Advanced Melanoma
Megan Brooks January 05, 2022 For untreated advanced melanoma, the fixed-dose combination of relatlimab and nivolumab is a “game changer that we have been waiting 10 years for,” Hussein Tawbi, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, told Medscape Medical News about today’s publication of the phase 2/3 RELATIVITY-047 trial. Progression-free survival (PFS) was “essentially double” with...
Post
Nivolumab effective treatment for malignant mesothelioma
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (Singapore–January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST)– Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. Malignant mesothelioma is an...